Wolverine
Also called BPC-157 + TB-500
No single human route established in this referenceEvidence gap
Research reference
Evidence gap
Wolverine blend evidence gap
No source-backed schedule
No established human course
When results may show
Wolverine
Evidence gap- When change was measured
- No measured human outcome window identified for this exact material.
- When to assess
- No established human course
- Conditions and limitations
- No exact-product primary protocol located in this review. No exact-blend primary protocol was located. Separate BPC-157 and full-length thymosin beta-4 findings do not validate this blend, its ratio, or TB-500 fragment equivalence.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
No direct outcome source identified. See the compound page for evidence grading.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
What is in a 10 mg Wolverine vial
| Component | Share | Per vial |
|---|---|---|
| BPC-157 | 50% | 5 mg |
| TB-500 | 50% | 5 mg |
Every draw has these same proportions.
Modelled level — every day
One curve per component: the components clear at very different rates.
BPC-157 (in Wolverine)TB-500 (in Wolverine)